Kathryn Jensen

1.4k total citations
18 papers, 1.0k citations indexed

About

Kathryn Jensen is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Kathryn Jensen has authored 18 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Epidemiology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Infectious Diseases. Recurrent topics in Kathryn Jensen's work include Respiratory viral infections research (13 papers), Neonatal Respiratory Health Research (6 papers) and Pneumonia and Respiratory Infections (4 papers). Kathryn Jensen is often cited by papers focused on Respiratory viral infections research (13 papers), Neonatal Respiratory Health Research (6 papers) and Pneumonia and Respiratory Infections (4 papers). Kathryn Jensen collaborates with scholars based in United States, United Kingdom and Chile. Kathryn Jensen's co-authors include M. Pamela Griffin, Genevieve A. Losonsky, Mark T. Esser, Gabriel J. Robbie, Filip Dubovsky, Therese Takas, Anis A. Khan, Tonya Villafana, William F. Dall’Acqua and Nita Patel and has published in prestigious journals such as PEDIATRICS, Antimicrobial Agents and Chemotherapy and The Lancet Infectious Diseases.

In The Last Decade

Kathryn Jensen

18 papers receiving 972 citations

Peers

Kathryn Jensen
Allison August United States
P. E. Taylor United States
Shelley Segal United Kingdom
Benoît Callendret Netherlands
Nicholas Roy Payne United Kingdom
David Beatty South Africa
Michael E. Abram United States
Stephanie Jones United Kingdom
D Kumararatne United Kingdom
Johannes Trück Switzerland
Allison August United States
Kathryn Jensen
Citations per year, relative to Kathryn Jensen Kathryn Jensen (= 1×) peers Allison August

Countries citing papers authored by Kathryn Jensen

Since Specialization
Citations

This map shows the geographic impact of Kathryn Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn Jensen more than expected).

Fields of papers citing papers by Kathryn Jensen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn Jensen. The network helps show where Kathryn Jensen may publish in the future.

Co-authorship network of co-authors of Kathryn Jensen

This figure shows the co-authorship network connecting the top 25 collaborators of Kathryn Jensen. A scholar is included among the top collaborators of Kathryn Jensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathryn Jensen. Kathryn Jensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Domachowske, Joseph B., Anis A. Khan, Kathryn Jensen, et al.. (2018). A Single Dose Monoclonal Antibody Immunoprophylaxis Strategy to Prevent Respiratory Syncytial Virus Disease in All Infants: Results of the First in Infant Study with medi8897. PEDIATRICS. 141(1_MeetingAbstract). 256–256. 1 indexed citations
2.
3.
Domachowske, Joseph B., Anis A. Khan, Mark T. Esser, et al.. (2018). Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. The Pediatric Infectious Disease Journal. 37(9). 886–892. 160 indexed citations
4.
Takas, Therese, et al.. (2017). A Phase 2a Study to Evaluate the Safety of MEDI8852 in Outpatient Adults with Acute, Uncomplicated Influenza A. Open Forum Infectious Diseases. 4(suppl_1). S519–S519. 8 indexed citations
5.
Domachowske, Joseph B., Anis A. Khan, Mark T. Esser, et al.. (2017). A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897. Open Forum Infectious Diseases. 4(suppl_1). S37–S37. 3 indexed citations
6.
Griffin, M. Pamela, Anis A. Khan, Mark T. Esser, et al.. (2016). Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults. Antimicrobial Agents and Chemotherapy. 61(3). 113 indexed citations
7.
Yu, Xiang‐Qing, Gabriel J. Robbie, Yuling Wu, et al.. (2016). Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults. Antimicrobial Agents and Chemotherapy. 61(1). 104 indexed citations
8.
O’Brien, Katherine L., Aruna Chandran, Robert Weatherholtz, et al.. (2015). Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. The Lancet Infectious Diseases. 15(12). 1398–1408. 122 indexed citations
9.
Griffin, M. Pamela, Anis A. Khan, Kathryn Jensen, et al.. (2015). A Passive Vaccine Approach to Respiratory Syncytial Virus Prophylaxis for All Infants: Results of a Phase 1 Study in Healthy Adult Volunteers. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations
10.
Makari, Doris, Kathryn Jensen, Brian Harris, & Hasan S. Jafri. (2014). Randomized, Double-Blind Study of the Safety of the Liquid Versus Lyophilized Formulation of Palivizumab in Premature Infants and Children with Chronic Lung Disease of Prematurity. Infectious Diseases and Therapy. 3(2). 339–347. 7 indexed citations
11.
Ramilo, Octavio, Rosanna Lagos, Xavier Sáez‐Llorens, et al.. (2013). Motavizumab Treatment of Infants Hospitalized With Respiratory Syncytial Virus Infection Does Not Decrease Viral Load or Severity of Illness. The Pediatric Infectious Disease Journal. 33(7). 703–709. 67 indexed citations
12.
Robbie, Gabriel J., William F. Dall’Acqua, Kathryn Jensen, et al.. (2013). A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults. Antimicrobial Agents and Chemotherapy. 57(12). 6147–6153. 245 indexed citations
13.
Anderson, Evan J., Eric A. F. Simões, Jim Buttery, et al.. (2012). Prevalence and Characteristics of Human Metapneumovirus Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Tract Infection. Journal of the Pediatric Infectious Diseases Society. 1(3). 212–222. 30 indexed citations
14.
15.
Feltes, Timothy F., Henry M. Sondheimer, Robert Tulloh, et al.. (2010). 176 A Randomized Controlled Trial of Rsv Prophylaxis with Motavizumab Vs Palivizumab in Young Children with Hemodynamically Significant Congenital Heart Disease. Pediatric Research. 68. 92–92. 2 indexed citations
16.
Crisp, Brian F., Kathryn Jensen, & Yael Shomer. (2007). Magnitude and vote seeking. Electoral Studies. 26(4). 727–734. 58 indexed citations
17.
Jensen, Kathryn, et al.. (1976). Psychiatric patients' views of strategies for the prevention of problems in living.. Professional Psychology. 7(1). 53–60. 2 indexed citations
18.
Jensen, Kathryn. (1976). [Adverse effects of naproxen].. PubMed. 138(51). 3284–3284. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Allison August Breakdown of academic impact, for papers by P. E. Taylor Breakdown of academic impact, for papers by Shelley Segal Breakdown of academic impact, for papers by Benoît Callendret Breakdown of academic impact, for papers by Nicholas Roy Payne Breakdown of academic impact, for papers by David Beatty Breakdown of academic impact, for papers by Michael E. Abram Breakdown of academic impact, for papers by Stephanie Jones Breakdown of academic impact, for papers by D Kumararatne Breakdown of academic impact, for papers by Johannes Trück
Rankless by CCL
2026